ORIGIN trial of Lantus(Sanofi)shows no CV effect or cancer risk

The landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention)showed that Lantus (insulin glargine [rDNA] injection) from Sanofi had no statistically significant positive or negative impact on cardiovascular outcomes versus standard care during the study period. Results also showed that insulin glargine delayed progression from pre-diabetes to Type 2 Diabetes and there was no association between insulin glargine use and increased risk of any cancer. The study findings were presented at the American Diabetes Association 72nd Scientific Sessions and are to be published online in the New England Journal of Medicine.